UroGen Pharma Ltd (NASDAQ:URGN)’s traded shares stood at 1.84 million during the last session, with the company’s beta value hitting 1.11. At the close of
In the last trading session, 2.27 million UroGen Pharma Ltd (NASDAQ:URGN) shares changed hands as the company’s beta touched 0.82. With the company’s per share
UroGen Pharma Ltd (NASDAQ:URGN) has a beta value of 0.35 and has seen 2.09 million shares traded in the last trading session. The company, currently
During the last session, UroGen Pharma Ltd (NASDAQ:URGN)’s traded shares were 3.96 million, with the beta value of the company hitting 0.40. At the end
UroGen Pharma Ltd (NASDAQ:URGN)’s traded shares stood at 2.67 million during the last session, with the company’s beta value hitting 0.45. At the close of
In the last trading session, 20.04 million UroGen Pharma Ltd (NASDAQ:URGN) shares changed hands as the company’s beta touched 0.39. With the company’s per share
UroGen Pharma Ltd (NASDAQ:URGN) has a beta value of 0.39 and has seen 3.92 million shares traded in the last trading session. The company, currently
During the last session, UroGen Pharma Ltd (NASDAQ:URGN)’s traded shares were 2.33 million, with the beta value of the company hitting 0.42. At the end
In the last trading session, 2.33 million shares of the UroGen Pharma Ltd (NASDAQ:URGN) were traded, and its beta was 0.46. Most recently the company’s
Marketing Sentinel delivers exclusive content, news, articles, and comprehensive coverage of events in the USA and worldwide with a commitment to reliability, objectivity, and timeliness.
© 2024, Powered by Smart TechOne